Non–small cell lung cancer (NSCLC) harbors a relatively high mutational landscape, and high tumor mutation burden tends to correlate with clinical benefits of PD-L1/PD-1 blockade treatments (Lawrence et al., 2013; Yarchoan et al., 2017). The gene discussed is PDCD1; the disease is lung cancer.